{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-24-000015","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.684790+00:00","generated_at":"2026-06-05T12:35:14.175721+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tarsus Q4 XDEMVY sales $13.1M; positive Phase 2a rosacea data","bullets":["XDEMVY net product sales $13.1M in Q4, $14.7M total since late-August launch; >17,400 bottles dispensed.","Positive Phase 2a Galatea trial for TP-04 in papulopustular rosacea: statistically significant improvements in lesions and IGA score vs vehicle at Week 12.","Q4 net loss $41.9M ($1.31 EPS); full-year net loss $135.9M ($4.62 EPS).","Cash, equivalents and marketable securities $227.4M as of Dec 31, 2023.","~6,000 ECPs have started patients on XDEMVY; >50% prescribed to multiple patients as of Feb 23."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-24-000015","json":"https://secwatch.observer/filing/0001819790-24-000015.json","markdown":"https://secwatch.observer/filing/0001819790-24-000015.md","text":"https://secwatch.observer/filing/0001819790-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000015/0001819790-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000015/tars-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:35:14.175721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a3259cb18c7d7de4a30ac22474432d641c2e44ec","claim":"Tarsus Pharmaceuticals, Inc. reported Full Year 2023 results: revenue $17.4 million.","evidence_excerpt":"Total revenues were $17.4 million, driven primarily by $14.7 million in XDEMVY net product sales, representing approximately four months of sales following the launch in late August.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000015/0001819790-24-000015-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Revenue","value":"$17.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e982cfef05912e7ea956924bbef0949d8df0810b","claim":"Tarsus Pharmaceuticals, Inc. reported Fourth Quarter 2023 results: revenue $13.1 million, net income $(41.9 million), EPS $(1.31).","evidence_excerpt":"Recent Business Achievements Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and $14.7 million in the first four months since launch Delivered more than 17,400 bottles of XDEMVY to patients Continued pipeline execution – reported positive","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000015/0001819790-24-000015-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter 2023"},{"label":"Revenue","value":"$13.1 million"},{"label":"Net income","value":"$(41.9 million)"},{"label":"EPS","value":"$(1.31)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}